HER2 receptor
E261824
cell surface protein
human protein
proto-oncogene protein
receptor tyrosine kinase
transmembrane receptor
The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
All labels observed (4)
| Label | Occurrences |
|---|---|
| HER2 receptor canonical | 5 |
| HER2 protein | 1 |
| NEU proto-oncogene protein | 1 |
| neu oncogene protein | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2370957 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: HER2 receptor Context triple: [Herceptin, targets, HER2 receptor]
-
A.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
B.
EGF
EGF is the ICAO airline designator used to identify American Eagle Airlines in aviation operations and communications.
-
C.
P-glycoprotein
P-glycoprotein is a membrane-bound efflux transporter protein that pumps various drugs and xenobiotics out of cells, influencing their absorption, distribution, and resistance profiles.
-
D.
programmed death-ligand 1
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
-
E.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: HER2 receptor Target entity description: The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
-
A.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
B.
EGF
EGF is the ICAO airline designator used to identify American Eagle Airlines in aviation operations and communications.
-
C.
P-glycoprotein
P-glycoprotein is a membrane-bound efflux transporter protein that pumps various drugs and xenobiotics out of cells, influencing their absorption, distribution, and resistance profiles.
-
D.
programmed death-ligand 1
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein expressed on various cells that suppresses T-cell activity by engaging PD-1, enabling tumors to evade immune surveillance.
-
E.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
- F. None of above. chosen
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
cell surface protein
ⓘ
human protein ⓘ proto-oncogene protein ⓘ receptor tyrosine kinase ⓘ transmembrane receptor ⓘ |
| activatesPathway |
JAK-STAT signaling pathway
ⓘ
MAPK signaling pathway ⓘ PI3K-AKT signaling pathway ⓘ |
| associatedWithPrognosis | poor prognosis in breast cancer when overexpressed ⓘ |
| biologicalProcess |
cell differentiation
ⓘ
cell proliferation ⓘ cell survival ⓘ epithelial cell development ⓘ |
| chromosomalLocationOfGene | 17q12 ⓘ |
| clinicalBiomarkerFor |
HER2-positive breast cancer
ⓘ
HER2-positive gastric cancer ⓘ |
| doesNotBind | known soluble ligand ⓘ |
| encodedByGene |
ERBB2
ⓘ
surface form:
ERBB2 gene
|
| formsHeterodimerWith |
EGFR
ⓘ
ERBB3 ⓘ ERBB4 ⓘ |
| hasAlternativeName |
CD340
ⓘ
ERBB2 ⓘ ERBB2 ⓘ
surface form:
HER-2/neu
HER2 receptor ⓘ
surface form:
neu oncogene protein
|
| hasDomain |
extracellular ligand-binding domain
ⓘ
intracellular tyrosine kinase domain ⓘ single-pass transmembrane domain ⓘ |
| locatedIn | plasma membrane ⓘ |
| memberOf |
ERBB2
ⓘ
surface form:
ERBB receptor family
epidermal growth factor receptor family ⓘ |
| molecularFunction |
ATP binding
ⓘ
protein tyrosine kinase activity ⓘ transmembrane signaling receptor activity ⓘ |
| overexpressionAssociatedWith |
bladder cancer
ⓘ
breast cancer ⓘ colorectal cancer ⓘ endometrial cancer ⓘ gastric cancer ⓘ gastroesophageal junction cancer ⓘ lung cancer ⓘ ovarian cancer ⓘ |
| postTranslationalModification |
glycosylation
ⓘ
phosphorylation ⓘ |
| targetOfDrug |
ado-trastuzumab emtansine
ⓘ
fam-trastuzumab deruxtecan ⓘ lapatinib ⓘ neratinib ⓘ pertuzumab ⓘ Herceptin ⓘ
surface form:
trastuzumab
tucatinib ⓘ |
| usedIn |
molecular classification of breast cancer
ⓘ
selection of targeted therapy in oncology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: HER2 receptor Description of subject: The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
Referenced by (8)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
neu oncogene protein